HS
TARS icon

HighVista Strategies’s Tarsus Pharmaceuticals TARS Stock Holding History

HighVista Strategies’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.48M Buy
87,060
+34,596
+66% +$2.21M 1.25% 23
2026
Q1 		$3.68M Sell
52,464
-1,100
-2% -$76.9K 1.02% 24
2025
Q4 		$4.39M Buy
53,564
+28,710
+116% +$2.14M 1.13% 28
2025
Q3 		$1.48M Buy
24,854
+13,174
+113% +$649K 0.36% 86
2025
Q2 		$473K Buy
+11,680
New +$526K 0.17% 129
2021
Q2 		– Sell
-21,084
Closed -$680K – 142
2021
Q1 		$680K Buy
+21,084
New +$780K 0.51% 43

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

HighVista Strategies's TARS Position: Q2 2026 in Review

HighVista Strategies increased its Tarsus Pharmaceuticals (TARS) stake by 66% in Q2 2026, buying an estimated $2.21M and bringing the position to 87,060 shares worth $5.48M. The position accounts for 1.25% of the portfolio, ranked #23.

HighVista Strategies first reported a position in TARS in Q1 2021 and has held it in 6 quarters since. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • HighVista Strategies held 87,060 shares of Tarsus Pharmaceuticals worth $5.48M as of Q2 2026.
  • HighVista Strategies bought 34,596 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $2.21M.
  • Tarsus Pharmaceuticals made up 1.25% of HighVista Strategies's portfolio in Q2 2026, its #23 holding.
  • HighVista Strategies first reported a position in Tarsus Pharmaceuticals in Q1 2021 and has held it in 6 quarters since.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.